6th Age-Related Disease Therapeutics Summit – What’s it about?
Join the biopharma industry's premier event dedicated to accelerating the development of treatments for age-related diseases. Over three packed days of content, delve into the latest advancements alongside 20+ leading experts.
Here's what awaits you:
- Explore novel strategies targeting the hallmarks of aging, including senescence and bioinformatics.
- Discover cutting-edge research defining quantitative endpoints for improved clinical translation.
- Navigate the evolving landscape of drug development and the 2024 investment and partnership market.
Connect and collaborate with 60+ attendees, across 3 days of content, from leading biopharma companies like Takeda, Eli Lilly & Co., NeuroAge Therapeutics, and Turn Bio to gain the knowledge and insights you need to commercialize your pipeline and bring transformative age-related disease therapies to patients.
Join Your Peers to:
Tackle the challenges surrounding clinical trial design for age-related indications to increase the momentum therapeutics through translation and into the clinic and make approved drugs targeting aging a reality.
Gain a deeper understanding on how to position yourself best for partnership and investment opportunities with Eli Lilly, BioAge and Aging Biotech to grow your company whilst ensuring commercial and therapeutic success.
Delve into the current biomarkers of aging landscape with Takeda, Turn Bio and NeuroAge to understand the novel technologies being used in biomarker discovery to enable precision approaches to aging-related interventions.
Dive into the latest updates in targeting cellular senescence and telomere targeted therapies with Rubedo Life Sciences, Dorian Therapeutics and Rejuvenation Biotech to stay ahead of the curve with the latest updates in aging research and innovation and advance your therapy through translation and into the clinic.
Explore current approaches in selecting an appropriate surrogate endpoint for aging to streamline clinical trials and ensure reliable and valid clinical data to set up the potential for therapies being used off-label in the future with Fountain Therapeutics.
Hear From Your Peers Why You Should Attend:
“A great aging/longevity summit focussed on therapeutics well on their way from basic science towards use in people, one of the few on the west coast.”
Karl Pfleger, Investor, Founder, AgingBiotech.com
“Intimate setting, great quality of speakers, attendees and the opportunity to network.”
Faizan Zubair, Takeda